Oncotarget is the leading online journal that covers oncology topics. The journal invites articles from diverse writers. The word Oncotarget was derived from oncology, which is the study of cellular functions. Oncology goes beyond the study of molecules, aging, and cancer therapies. It covers topics such as microbes, neurons, and lymphocytes. Oncotarget is an archive of multidisciplinary journals. Users can access all journals published on the directory free of charge. These journals are usually published every week. Oncotarget issues can also be printed on request.
Since 2010, Impact Journals have always published the reading materials. Oncotarget’s materials on scimagojr.com are released under the Creative Commons Attribution 3.0 License. They are tagged under ISSN 1949-2553 and OCLC no. 408119940.
Oncotarget’s mission is to avail scientific resources to people who require them for research or other educational purposes. The online journal frequently releases journals written by expert researchers. The language used in the publications is comprehensible. Oncotarget’s journals also target readers from all parts of the world.
Oncotarget also focuses on eliminating the border differences that exist between specialties. The directory links diverse biomedical science fields and offers readers a comprehensive way of navigating through the fields. Biomedical science is a broad area of research. Topics are linked on Oncotarget to educate readers on applications of clinical and basic science. This knowledge can be used in finding an effective treatment for diseases.
The repository attributes its success to editors and researchers who publish articles weekly. It boasts contributions from renowned scientists who have been instrumental in progressing science as a field. The repository’s contributors on endnote.com believe that medical studies lead to the eradication of diseases hence longevity in humans. The repository has managed to expand its coverage beyond oncological topics.
Chief Editors of the repository are Mikhail Blagosklonny and Andrei V. Gudkov. These editors ensure that all informative materials submitted are written in English. Mikhail Blagosklonny is a medical scholar whose hypothesis on aging and cancer has been referenced severally in research publications. According to him, cancer patients can live longer if they are treated with rapamycin. He currently serves as an oncology lecturer at the Roswell Park Cancer Institute. He furthers the research on cancer and creation of therapies for managing cancer. Andrei V. Gudkov, whose research publications are also relevant in biomedical studies, also works at the institution.